statement
In the 600mg high-dose maintenance group, the ACR20 response rate was 92.5%, with nearly all patients maintaining response through week 28.
A statement by 현대차증권 제약/바이오/의료기기 김현석. Statements are as reported by the cited publishers — not verified by DecisionGateway.
600mg 고용량 유지군에서는 ACR20 반응률이 92.5%로 거의 모든 환자들이 28주차까지 반응률을 유지하며
Related claims
The 600mg continuous dosing group recorded an ACR20 value of 92.5%, demonstrating excellent efficacy in absolute terms.report author · statementThe high placebo response rate is because all patients received 600mg high dose for 16 weeks in Period 1, not because of a large placebo effect; 75% of the placebo group maintained ACR20 through week 28.현대차증권 제약/바이오/의료기기 김현석 · statementThe 300mg low-dose group showed no maintenance effect: patients falling below ACR20 were 3 of 40 (7.5%) in 600mg, 9 of 36 (25.0%) in 300mg, and 10 of 41 (24.4%) in placebo, meaning the low-dose group was effectively without efficacy.현대차증권 제약/바이오/의료기기 김현석 · statementACR20 reached 92.5%, surpassing 72.7% at week 16 and meeting expectations.하나증권 제약/바이오 김선아 · statementIMVT-1402 in refractory rheumatoid arthritis achieved statistical significance in the Period 2 ACR20 response rate, with the 600mg group meeting key endpoints at week 28 on both ACR20 and ACR50 versus placebo.현대차증권 제약/바이오/의료기기 김현석 · statementIn the D2T RA Phase 2b Period 2 results, the 600mg continuous dosing group achieved statistical significance (p-value), a surprise exceeding market expectations.report author · statement